Literature DB >> 26080459

In vitro and in vivo study on the effect of antifungal agents on hematopoietic cells in mice.

Maria Samalidou1, Dimitris Bougiouklis2, Timoleon-Achilleas Vyzantiadis3, Joseph Meletiadis4, Nikolaos Monokrousos5, Eleni Siotou2, Afroditi Sivropoulou6, Achilles Anagnostopoulos2, Damianos Sotiropoulos2.   

Abstract

Liposomal amphotericin B, voriconazole, and caspofungin are currently used for systemic and severe fungal infections. Patients with malignant diseases are treated with granulocyte-colony stimulating factor (G-CSF) for the recovery of granulocytes after chemotherapy or hematopoietic cell (HC) transplantation. Since they have a high incidence of fungal infections, they inevitably receive antifungal drugs for treatment and prophylaxis. Despite their proven less toxicity for various cell types comparatively with amphotericin B and the decrease in the number of leukocytes that has been reported as a possible complication in clinical studies, the effect of liposomal amphotericin B, voriconazole, and caspofungin on HCs has not been clarified. The present study aimed to examine the in vitro and in vivo effect of these three modern antifungals on HCs. Colony-forming unit (CFU) assays of murine bone marrow cells were performed in methylcellulose medium with or without cytokines and in the presence or absence of various concentrations of liposomal amphotericin B, voriconazole, and caspofungin. In the in vivo experiments, the absolute number of granulocytes was determined during leukocyte recovery in sublethally irradiated mice receiving each antifungal agent separately, with or without G-CSF. In vitro, all three antifungal drugs were nontoxic and, interestingly, they significantly increased the number of CFU-granulocyte-macrophage colonies in the presence of cytokines, at all concentrations tested. This was contrary to the concentration-dependent toxicity and the significant decrease caused by conventional amphotericin B. In vivo, the number of granulocytes was significantly higher with caspofungin plus G-CSF treatment, higher and to a lesser extent higher, but not statistically significantly, with voriconazole plus G-CSF and liposomal amphotericin B plus G-CSF treatments, respectively, as compared with G-CSF alone. These data indicate a potential synergistic effect of these antifungals with the cytokines, in vitro and in vivo, with subsequent positive effect on hematopoiesis.
© 2015 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  caspofungin; cell culture; granulocytes; hematopoiesis; liposomal amphotericin B; voriconazole

Mesh:

Substances:

Year:  2015        PMID: 26080459      PMCID: PMC4935346          DOI: 10.1177/1535370215590820

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  19 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 2.  AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.

Authors:  Jill Adler-Moore; Richard T Proffitt
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 3.  TLRs control hematopoiesis during infection.

Authors:  Alberto Yáñez; Helen S Goodridge; Daniel Gozalbo; M Luisa Gil
Journal:  Eur J Immunol       Date:  2013-10       Impact factor: 5.532

4.  Toll-like receptor 4/stem cell antigen 1 signaling promotes hematopoietic precursor cell commitment to granulocyte development during the granulopoietic response to Escherichia coli bacteremia.

Authors:  Xin Shi; Robert W Siggins; William L Stanford; John N Melvan; Marc D Basson; Ping Zhang
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

5.  Direct Toll-like receptor-mediated stimulation of hematopoietic stem and progenitor cells occurs in vivo and promotes differentiation toward macrophages.

Authors:  Javier Megías; Alberto Yáñez; Silvia Moriano; José-Enrique O'Connor; Daniel Gozalbo; María-Luisa Gil
Journal:  Stem Cells       Date:  2012-07       Impact factor: 6.277

6.  Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.

Authors:  Silvia Bellocchio; Roberta Gaziano; Silvia Bozza; Giordano Rossi; Claudia Montagnoli; Katia Perruccio; Mario Calvitti; Lucia Pitzurra; Luigina Romani
Journal:  J Antimicrob Chemother       Date:  2005-01-13       Impact factor: 5.790

Review 7.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS.

Authors:  R J Coker; M Viviani; B G Gazzard; B Du Pont; H D Pohle; S M Murphy; J Atouguia; J L Champalimaud; J R Harris
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

9.  Caspofungin reduces the incidence of fungal contamination in cell culture.

Authors:  Luis R Martinez; Patricia Ntiamoah; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Mycopathologia       Date:  2007-09-22       Impact factor: 2.574

10.  Protective effect of granulocyte-colony stimulating factor against amphotericin B-induced myelosuppression in vitro.

Authors:  B S Charak; E G Brown; A Mazumder
Journal:  Br J Haematol       Date:  1994-12       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.